BLOG / 🇺🇸 United States / broad market · · monthly

US Pre-Market SEC Filings Roundup — November 05, 2026

USA Before-Market Intelligence

By Gunpowder Editorial ·

31 high priority 19 medium priority 50 total filings analysed

Executive Summary

Across 50 overnight SEC filings (Nov 4-5, 2026), the dominant theme is mixed results: top-line growth is common but is frequently flattered by one-time items, acquisitions, divestitures, or currency effects, while cash generation, margins and organic momentum lag headline numbers.

Notable period-over-period strength appears at Dorian LPG (revenue +78% YoY, net income lifted by vessel disposal gains), Oscar Health (revenue +72% YoY, guidance raised to $850M-$950M, though including a one-time $250M risk adjustment benefit), Graham Corp (net income +50% YoY, record backlog of $561.3M, but orders -11%), Haemonetics (revenue +9.3%, guidance raised), and Tapestry (net sales +11.1%, EPS +37.5%, but equity dropped sharply on $603M of buybacks). Weakness is concentrated in consumer and cash-burning names: Shutterstock (revenue -33% YoY, $377M nine-month goodwill impairment), Papa John's (revenue -10.5%, stockholder deficit widening), and the Natera insider selling cluster. Capital allocation is active: HF Sinclair is repurchasing shares privately under a $1.5B program, Lincoln National resumed buybacks while retiring preferred stock, and AngloGold paid a $361M dividend while FCF fell 22%. Biotech and SPAC filings show heavy cash burn funded by equity raises, and the sector shows a clear pattern of dilution-driven per-share optics. The most market-moving items are the Charming Medical Nasdaq delisting (trading suspension Nov 9), the Ares/MidCap merger, and the Cigna guidance raise with its $3B modernization plan.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 10-Q · DEF 14A · 8-K · 425 · Form 4 · Schedule 13D · S-3

Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from November 04, 2026.

Investment Signals (14)

  • ▲

    Revenue +78.4% YoY to $221.3M, net income $213.9M vs $55.4M, cash up to $578.8M, debt reduced (repaid $310.3M vs $229.3M borrowed)

  • ▲

    Revenue +72% YoY to $5.14B, earnings from operations $178M vs $(129)M a year earlier, MLR improved to 84.0% from 88.5%, FY2026 operating earnings outlook raised to $850M-$950M

  • ▲

    Raised FY2026 adjusted EPS outlook to at least $30.60, adjusted income $7.98/share vs $7.83, announced $3B 'Accelerate to One' program; PBS profit fell 22%

  • ▲

    Q2 revenue +9.3% reported / +10.0% organic, GAAP EPS $1.00 vs $0.81, reported revenue guidance raised to 8-11% and organic to 6-9%; MedSurg grew only 5.1% and adjusted margin fell 40 bps

  • ▲

    Net income +50.1% YoY, gross margin +650 bps to 28.2%, adjusted EBITDA +64%, record backlog $561.3M; however orders fell 11% and Energy & Process sales fell 17%

  • Tapestry ↓ (BULLISH)
    ▲

    Net sales +11.1% to $1,894M, diluted EPS $1.76 vs $1.28 (+37.5%), operating margin ~22.4% vs 19.2%, but cash fell to $599M and equity dropped to $344M after $603M of buybacks

  • ▲

    Revenue +12.2% YoY, ARR $1.58B (from $1.41B), operating income up to $122.6M from $84.5M; operating cash flow down to $109.4M from $116.4M

  • ▲

    Repurchasing 2.1M shares from REH Advisors at $110.81 (~$233M), 24th private repurchase; cumulative program $1B of $1.5B used

  • PRB realized cash margin flipped to +$0.80/ton from -$0.57 QoQ; repurchased $84.7M of stock and declared $0.10 dividend; High CV margin per ton down ~21% YoY

  • EBITDA +12% YoY to $1,568M, FY2026 guidance reaffirmed, but gold output -9%, AISC +26% to $2,170/oz, FCF -22% to $722M

  • ▲

    Q3 revenue -33.1% YoY to $173.9M, $203.3M Q3 goodwill impairment ($377.1M YTD), operating cash flow -72% for nine months

  • Papa John's (BEARISH)
    ▲

    Q3 revenue -10.5% to $454.8M, net income -33.4%, nine-month operating cash flow -44.9%, stockholders' deficit widened to $(438.5)M

  • Charming Medical (MCTA) (BEARISH)
    ▲

    Nasdaq delisting determination; trading suspended at open Nov 9, 2026 unless appeal requested by Nov 5; follows SEC suspension over social-media manipulation

  • Natera (NTRA) (BEARISH)
    ▲

    Cluster of Form 4 sales in one filing window: CEO Chapman sold 2,866 shares at $415.64 (~$1.19M), Executive Chairman Rabinowitz sold 731 at $400.29 (~$293K), plus President Fesko, CFO Brophy, General Counsel Rabinowitz and director Sheena, all 10b5-1 plans

Risk Flags (10)

  • $377.1M nine-month goodwill impairment; goodwill fell from $574.6M to $196.9M, revenue down 22.7% YTD, Q3 gross margin ~51.9% vs ~60.6%

  • Nasdaq removal after SEC trading suspension tied to alleged social-media price manipulation; OTC liquidity uncertain

  • $250M one-time risk adjustment benefit flatters Q3 revenue; favorable prior-period development halved to $42M from $84M; Cigna+Oscar membership fell to zero

  • Annuity net outflows $2.7B (vs $1.1B), Retirement Plan Services swung to $1.9B net outflows from $755M inflows, Group Protection operating income -69% YoY on disability experience

  • Papa John's/Balance Sheet [MEDIUM RISK]
    ▼

    Stockholders' deficit $(438.5)M, liabilities $1.21B vs assets $772.8M, cash down to $26.8M; company-owned sales -22% on refranchising

  • ▼

    Total cash costs +25% to $1,534/oz, Sukari output -21%, TRIFR rose to 1.09 from 0.79

  • Nine-month operating cash use widened to $70.9M from $56.2M, stockholders' deficit $(130.5)M, new $50.2M long-term debt, revenue zero vs $0.5M

  • Amylyx/Operating Burn↓ [MEDIUM RISK]
    ▼

    Q3 opex +38% to $49.7M, nine-month net loss $130.2M vs $111.7M; reliant on $544.6M Q3 financing

  • ▼

    Net loss $74M, adjusted EBITDA margin down to 13% from 14%, principal debt ~$1.05B vs ~$97M liquidity, Proppant margin only 2%

  • G&A +49.8% YoY, nine-month operating cash burn +32% to $49.2M, weighted share count ~3.9x (55.1M vs 14.0M) after $431.3M offering

Opportunities (9)

  • Ares Capital / MidCap Financial (MFIC) (OPPORTUNITY)
    ◆

    Definitive merger agreement, stock-and-cash, ~30% premium to MFIC's pre-announcement price; MFIC holders have a near-term re-rating catalyst pending stockholder and regulatory approvals; competing-bid risk is also flagged

  • Dorian LPG↓ (OPPORTUNITY)
    ◆

    Balance sheet deleveraging with cash at $578.8M and vessel disposal gains; a sustained tanker-market trough could reprice shares if further disposal proceeds return capital

  • Monte Rosa Therapeutics (GLUE) (OPPORTUNITY)
    ◆

    Q3 collaboration revenue $54.4M (vs $12.8M), net income $3.1M vs $27.1M loss, cash $582.6M funding into 2029; $37.5M milestone receipts not yet reflected in September cash

  • Cigna Group↓ (OPPORTUNITY)
    ◆

    Raised 2026 EPS floor to at least $30.60 with $3B modernization program and exit from individual medical; catalyst set for post-Investor Day upward estimate revisions

  • Haemonetics↓ (OPPORTUNITY)
    ◆

    Guidance raised with Apheresis +12.6% reported (+13.6% organic); if MedSurg stabilizes, margin recovery from 0-50 bps guide could drive upside

  • ◆

    PRB cash cost fell 9% to $13.49/ton, flipping margin positive; continued buybacks ($84.7M QoQ) plus $0.10 dividend support capital return thesis

  • HF Sinclair↓ (OPPORTUNITY)
    ◆

    Ongoing privately negotiated repurchases at $110.81 (~$233M closing ~Nov 6) with ~$493M authorization remaining, signaling management view on intrinsic value

  • Graham Corp↓ (OPPORTUNITY)
    ◆

    Record $561.3M backlog and raised gross margin guidance; a rebound in Energy & Process or orders would drive operating leverage

  • Bentley Systems↓ (OPPORTUNITY)
    ◆

    ARR growth to 13% constant currency, raised ARR growth range to 12.5-13.5%, net leverage 1.7x with undrawn revolver; recurring revenue visibility supports multiple

Sector Themes (6)

  • Earnings Quality Gap in Growth Names
    ◆

    Several headline beats rest on non-recurring items: Oscar's $250M risk adjustment benefit, Dorian's $63.6M and $93.7M vessel disposal gains, Monte Rosa's $50M milestone, Graham's $10M material receipt timing; underlying growth should be haircut 10-20% for valuation [IMPLICATION: discount headline EPS]

  • Impairments and Shrinking Revenue in Digital/Consumer
    ◆

    Shutterstock ($377M goodwill write-down), Papa John's (revenue -9% YTD), WW International (revenue -11%, offset by clinical mix shift to 25%) show legacy consumer franchises shrinking; restructuring-led margin gains (Shutterstock opex -24% to -36%) are cushioning but not reversing declines [IMPLICATION: expect further write-downs in subscription/consumer names]

  • Biotech Funding via Dilution
    ◆

    Avalo ($431M offering), Amylyx ($544.6M financing), Intensity (ATM dilution, share count +89%), and Cartesian (negative equity, new debt) show clinical-stage companies financing burn through equity; per-share loss improvements are largely share-count driven [IMPLICATION: favor cash-runway analysis over EPS trends]

  • Insurance: Growth Diverging from Flows and Claims
    ◆

    Cigna and Oscar improved medical cost ratios (MCR 84.0% Oscar, 85.0% Cigna), while Lincoln saw large annuity and retirement outflows and disability loss-ratio deterioration; sector earnings are supported by medical-cost discipline but investment-product flows are weakening [IMPLICATION: watch flow data as a leading indicator]

  • Capital Return Remains Active Among Cash-Generative Cyclicals
    ◆

    HF Sinclair (~$1B repurchased to date), Tapestry ($603M buybacks in Q1), Lincoln ($50M resumed), Core ($84.7M buybacks plus dividend), AngloGold ($361M dividend) continue returning cash even as FCF is pressured in gold and energy; buybacks at elevated prices may limit future flexibility if commodity or demand cycles turn [IMPLICATION: assess buyback quality against FCF]

  • Insider Selling Concentrated at Natera
    ◆

    Eight Form 4 filings in the window, mostly 10b5-1 plan sales near $388-$416, with CEO, Executive Chairman, CFO, President and General Counsel all participating; these are plan-based and modest relative to holdings, but the breadth of selling across senior management is a consistent pattern to track [IMPLICATION: low-conviction signal, monitor for plan changes]

Watch List (8)

  • Charming Medical (MCTA)
    👁

    Trading suspension effective at open Nov 9, 2026 absent appeal by Nov 5; monitor OTC migration and any appeal filing

  • Ares Capital / MidCap Financial
    👁

    Form N-14 and proxy filings, stockholder vote timing, and any competing proposal; no closing date disclosed

  • Closing of the 2.1M-share repurchase from REH Advisors on or about Nov 6, 2026; further privately negotiated purchases under the $493M remaining authorization

  • Exit from Individual and Family Plans medical effective Jan 1, 2027, and early progress on the $3B Accelerate to One initiative

  • Papa John's / Shutterstock
    👁

    Further refranchising, restructuring and any additional goodwill assessments as revenue declines continue

  • Natera (NTRA)
    👁

    Insider sales under 10b5-1 plans; watch for changes or new filings from CEO and Executive Chairman

  • Warrant exercisability begins 30 days after the Nov 4, 2026 merger (approximately Dec 4, 2026); Klein-related holder activity

  • Annual meetings on Dec 18, 2026 and Dec 7, 2026 respectively; watch Greenwave's Series B conversion approval (3,571,429 shares) and Xcel's equity plan expansion and note-conversion authority

Filing Analyses (50)
GRAHAM CORP 10-Q mixed materiality 8/10

05-11-2026

Graham Corp reported Q2 FY2027 (three months ended September 30, 2026) net sales of $69,760K, up 5.7% YoY from $66,027K, and net income of $4,637K, up 50.1% from $3,090K (diluted EPS $0.39 vs $0.28). Six-month net sales rose 16.1% to $141,102K and net income rose 11.3% to $8,549K. Performance was mixed: cost of products sold fell 3.1% in the quarter, lifting gross profit 37.5%, but SG&A rose 34.3% for the quarter, and the company issued roughly $50.5M of new common stock while holding $71.4M in cash after repaying its $13.0M long-term debt.

  • · Customer deposits rose to $129.66M from $102.42M at March 31, 2026, a major driver of operating cash flow
  • · Unbilled revenue declined to $44.52M from $59.87M, contributing a $15.33M operating cash inflow
  • · Long-term debt fully repaid to zero from $13.00M at March 31, 2026
  • · Depreciation rose to $3.46M from $2.17M and amortization of intangibles rose to $2.01M from $1.00M, reflecting the January 23, 2026 acquisition
  • · Capital expenditures fell to $4.86M from $11.15M year over year, a 56.6% decline
  • · Basic EPS for the six months rose to $0.73 from $0.70, a modest 4.3% increase despite a 16.1% sales increase, as share count expanded about 6.5%
  • · Other operating expense swung to a $0.19M expense in the quarter from $0.19M income in the prior-year quarter
Black Spade Acquisition III Co 10-Q mixed materiality 6/10

05-11-2026

Black Spade Acquisition III Co (BIII-UN), a blank-check SPAC, reported its Q3 2026 10-Q for the quarter ended September 30, 2026. Net income for the three months was $179,747 ($0.01 per share), driven by $1,604,947 of trust interest that offset $1,425,200 of G&A costs; for the nine months, net income was $2,115,385 ($0.09 per share). The trust account held $177,073,722 against 17,250,000 redeemable Class A shares at a redemption value of $10.27 per share, while the company's shareholders' deficit widened to $(8,357,382), reflecting ongoing operating costs and a $6,876,000 deferred underwriting fee.

  • · Net cash used in operating activities was $903,695 for the nine months, against an unrestricted cash balance that fell about 94% to $201,559 from $3,279,258 at year-end 2025.
  • · Related-party advances of $3,347,804 and a promissory note of $123,988 were repaid during the nine months, while accounts payable and accrued expenses rose to $1,675,910 from $43,299.
  • · Total liabilities more than doubled to $8,636,910, driven mainly by the $6,876,000 deferred underwriting fee now payable.
  • · Accretion of Class A shares to redemption value totaled $13,914,250 in the nine months, including $6,683,912 charged to additional paid-in capital and $7,230,338 to accumulated deficit.
  • · The over-allotment option was exercised in full on January 7, 2026, bringing Class A shares outstanding to 17,250,000.
INTENSITY THERAPEUTICS, INC. 10-Q mixed materiality 6/10

05-11-2026

Intensity Therapeutics reported a Q3 2026 net loss of $3.5 million ($1.09 per share), up 33% from $2.7 million in Q3 2025, as R&D spending rose 56% to $2.4 million and G&A rose 1% to $1.2 million. Nine-month net loss widened modestly to $9.0 million from $8.6 million, while cash and equivalents declined to $8.5 million from $11.9 million at year-end 2025. Equity financing via at-the-market offerings partly offset cash burn, and the company's share count rose sharply, reflecting the reverse stock split adjustment and continued dilution.

  • · Net cash used in operating activities was $6.7M for nine months 2026, roughly flat versus $6.8M in 2025.
  • · Accounts payable rose to $1.65M from $0.58M at year-end 2025, a 183% increase that may signal timing of vendor payments.
  • · Q3 2026 loss per share of $1.09 improved from $1.55, but this reflects a share count that grew to 3.26M weighted average from 1.72M, driven by dilutive ATM issuances.
  • · The CEO received 37,749 shares in lieu of a cash bonus, valued at $231K.
  • · Nine-month 2026 ATM proceeds of $3.3M were well below the $7.9M raised in the same period of 2025, and no public offerings occurred in 2026 versus $4.7M in 2025.
HAEMONETICS CORP 10-Q mixed materiality 7/10

05-11-2026

Haemonetics reported Q2 FY2027 (three months ended September 26, 2026) net revenues of $357.8M, up 9.3% YoY from $327.3M, with net income rising to $46.3M from $38.7M and diluted EPS of $1.00 versus $0.81. Six-month revenue reached $697.1M (+7.5% YoY) and six-month net income was $79.3M (+9.1%). However, growth was uneven: Q2 comprehensive income was $49.2M versus $34.4M, but six-month comprehensive income fell to $78.2M from $87.3M due to a swing in foreign currency translation, and operating cash flow, while higher at $180.4M versus $128.7M, was accompanied by a rise in long-term debt reduction activity and a $75.0M share repurchase in the prior-year period with none in the current period.

  • · Six-month comprehensive income declined to $78.2M from $87.3M despite higher net income, driven by a swing in foreign currency translation from a $14.9M gain to a $3.2M loss.
  • · Q2 SG&A grew 10.6% YoY to $118.4M, outpacing revenue growth of 9.3%.
  • · Q2 amortization of acquired intangibles fell 7.0% YoY and Q2 included no impairment, versus an $8.6M intangible impairment in the prior-year quarter.
  • · Interest and other expense rose to $22.1M for six months from $15.9M, a 39% increase that compressed pre-tax income growth.
  • · Long-term debt fell to $1,114.1M from $1,219.6M, reflecting a $100.0M revolver paydown, while $17.6M of contingent consideration was paid.
  • · A January 9, 2026 acquisition added $117.1M of developed technology and $52.1M of goodwill, with net assets acquired of $166.0M, financed alongside a $75.0M prior-year buyback that was not repeated this period.
DORIAN LPG LTD. 10-Q positive materiality 8/10

05-11-2026

Dorian LPG reported Q2 FY2027 (three months ended September 30, 2026) total revenues of $221.3M, up 78.4% YoY from $124.1M, and net income of $213.9M versus $55.4M a year earlier, driven largely by a $63.6M gain on vessel disposals. For the six months, revenues rose 96.5% to $409.2M and net income rose to $352.1M from $65.5M, with the period also including a $93.7M disposal gain. Balance sheet strengthened, with cash rising to $578.8M from $327.4M, though total debt was reduced and operating expenses (vessel operating and D&A) declined YoY.

  • · Vessels, net declined to $957.4M from $1,215.9M since March 31, 2026, reflecting vessel disposals; $78.8M of vessels classified as held for sale.
  • · Long-term debt was reduced: $310.3M repaid versus $229.3M of new borrowings in the six months, with current portion of debt falling to $43.7M from $100.2M.
  • · Operating lease right-of-use assets and lease liabilities both declined, and due from related parties rose to $159.5M (current) from $97.0M.
  • · Weighted average diluted shares were 42.9M for the quarter; diluted EPS was $4.98 versus $1.30 a year earlier.
  • · Dividends paid totaled $86.0M in the six months versus $47.6M a year earlier, with $1.00 per share declared each quarter.
  • · Charter hire expenses increased to $18.2M (three months) from $13.7M, and profit sharing expenses of $2.8M were incurred versus none in the prior year period.
Greenwave Technology Solutions, Inc. DEF 14A neutral materiality 6/10

05-11-2026

Greenwave Technology Solutions, Inc. (GWAV) filed its DEF 14A proxy statement on November 5, 2026 for a virtual 2026 Annual Meeting of Stockholders on December 7, 2026 at 12:30 p.m. ET, with a record date of October 23, 2026. Shareholders are asked to elect directors, ratify RBSM LLP as auditor for fiscal 2026, and approve the issuance of up to 3,571,429 shares of Common Stock upon conversion of 3,750 shares of Series B Preferred Stock under Nasdaq Listing Rule 5635(d). The filing reports 2,982,484 Common Shares and 450,000 Series A-1 Preferred Shares outstanding and entitled to vote.

  • · Series A-1 Preferred conversion is priced at 0.0001% of outstanding Common Stock, with voting capped at a 45% beneficial ownership limitation.
  • · Series B Preferred holders generally have no voting rights except as set out in the Certificate of Designations dated September 8, 2026 or required by Delaware law.
  • · Proposal 1 (director elections) and Proposal 3 (Series B share issuance) are non-routine matters, so broker non-votes will not count toward those outcomes.
  • · Proposal 3 requires a majority of shares present and entitled to vote; abstentions count as votes against.
  • · Stockholders wishing to attend as beneficial owners must submit legal proxy registration to Equity Stock Transfer by 5:00 p.m. ET on December 3, 2026.
  • · Requests for additional filing materials should be made by November 30, 2026.
Oscar Health, Inc. 8-K mixed materiality 8/10

05-11-2026

Oscar Health reported Q3 2026 total revenue of $5,139,298K (about $5.1B), up from $2,985,984K in Q3 2025 (+72%), and earnings from operations of $178,018K versus a $129,250K loss a year earlier. MLR improved to 84.0% from 88.5% and SG&A ratio fell to 14.0% from 17.5%, and management raised its full-year 2026 earnings from operations outlook to $850M-$950M from $600M-$800M. Performance was not uniformly positive: Q3 revenue included a one-time $250M risk adjustment benefit, favorable prior period development declined to $42M from $84M a year earlier, and effectuated membership figures show the company no longer has any Cigna+Oscar members.

  • · Q3 2026 revenue included a $250M one-time risk adjustment benefit, which flatters the year-over-year revenue comparison
  • · Favorable prior period development halved to $42M from $84M in Q3 2025
  • · Cigna+Oscar co-branded membership fell to zero from 5,168 in 2025 after the arrangement was not renewed
  • · Full-year revenue guidance was raised only modestly to $19.0B-$19.3B from $18.7B-$19.0B
  • · Effectuated membership in the Individual and Small Group offering rose about 27% to 2.69M from 2.11M
MidCap Financial Investment Corp 425 mixed materiality 8/10

05-11-2026

Ares Capital Corporation (ARCC) has entered into a definitive Agreement and Plan of Merger to acquire MidCap Financial Investment Corporation (MFIC) in a stock and cash transaction, disclosed via an Apollo Global Management Q3 2026 earnings call transcript filed under Rule 425. The purchase price reflects an approximately 30% premium to MFIC's pre-announcement stock price. The filing provides no specific deal value, share exchange ratio, or closing timeline, and the transaction remains subject to stockholder approval, regulatory approvals, and other conditions.

  • · Transaction structure is a combination of stock and cash consideration, with MFIC's special dividend from undistributed taxable income affecting the number of ARCC shares issued
  • · Completion is contingent on MFIC stockholder approval, required regulatory approvals, and ARCC registration statement (Form N-14) and Proxy Statement/Prospectus being filed and effective
  • · Merger Agreement may require MFIC to pay a termination fee in certain circumstances, and competing acquisition proposals are a identified risk
  • · Apollo stated the financial impact of the transaction is embedded within its 2027 management fee expectation guidance, which reflects a reduction in fees from MFIC
  • · ARCC was the largest publicly traded BDC by market capitalization as of September 30, 2026
HAEMONETICS CORP 8-K mixed materiality 7/10

05-11-2026

Haemonetics reported fiscal Q2 2027 (quarter ended September 26, 2026) revenue of $357.8 million, up 9.3% reported and 10.0% organic, with GAAP EPS of $1.00 and adjusted EPS of $1.35 (up 6.3%). Management raised reported revenue guidance to 8-11% and organic growth guidance to 6-9%, while adjusted operating margin expansion guidance was narrowed to 0-50 bps. Performance was mixed: Apheresis grew 12.6% reported (13.6% organic), but MedSurg grew only 5.1% reported (5.5% organic), and adjusted operating margin declined 40 bps year over year to 26.3%.

  • · Prior-year Q2 GAAP net income was $38.7M and GAAP EPS $0.81, implying 19.6% GAAP net income growth
  • · Effective income tax rate rose to 26.3% from 24.6%, driven by valuation allowances on deferred tax assets in jurisdictions with losses from recent acquisitions
  • · Operating cash flow benefited from favorable working capital timing; higher capex weighed on free cash flow
  • · Adjusted operating expenses rose 15.2%, far outpacing adjusted operating income growth of 7.8%, driven by personnel costs and freight
  • · Gross margin tailwind included tariff refunds, which are non-recurring in nature
  • · Tariff refunds and portfolio mix supported a 140 bps adjusted gross margin improvement, yet margin still contracted at the operating line
  • · Fiscal 2027 guidance now assumes high-single-digit Apheresis organic growth versus low-to-mid single digits previously, while MedSurg guidance remains mid-single digit
  • · Cash on hand rose $15.3M since fiscal 2026 year-end despite revolver repayments, capex and contingent consideration payments
ProFrac Holding Corp. 8-K mixed materiality 7/10

05-11-2026

ProFrac Holding Corp. (NASDAQ: ACDC) reported Q3 2026 total revenue of $511 million, up from $498 million in Q2, while net loss was $74 million, roughly in line with the $75 million loss in Q2. Adjusted EBITDA declined to $65 million (13% of revenue) from $69 million (14%) in Q2, though operating cash flow improved to $51 million and free cash flow turned positive at $14 million. Management expects Q4 2026 improvement in Stimulation Services and Proppant Production, while total principal debt stands at approximately $1.05 billion with about $97 million of liquidity.

  • · Net loss narrowed slightly from $75M to $74M, essentially flat.
  • · Stimulation Services margin is 9% and Proppant Production margin is only 2%, with West Texas proppant throughput recovering but the region remaining highly competitive.
  • · Adjusted EBITDA margin contracted from 14% to 13% of revenue.
  • · Liquidity of $97M includes only about $19M of cash excluding Flotek, and roughly $25M of total cash is inaccessible to the Company.
  • · Alpine's leverage covenant takes effect for the quarter ending March 31, 2028, and there is no assurance it can be met, modified or deferred.
  • · 2026 capex guidance was updated to $160M-$180M including Flotek, or $145M-$165M excluding Flotek.
  • · Management expects less seasonality in Q4 2026 than historically, and Q4 Stimulation Services results to improve sequentially despite year-end seasonality.
  • · The Company's 2026 guidance and the timing/amount of asset disposition proceeds carry explicit no-assurance language.
AngloGold Ashanti PLC 6-K mixed materiality 8/10

05-11-2026

AngloGold Ashanti reported Q3 2026 EBITDA of $1,568m, up 12% year-on-year, and a Q3 interim dividend of 71 US cents per share ($361m), with full-year 2026 guidance reaffirmed. However, gold production fell 9% YoY to 696,000oz, total cash costs rose 25% to $1,534/oz and AISC rose 26% to $2,170/oz, and free cash flow declined 22% YoY to $722m as capex and tax payments increased.

  • · Free cash flow declined 22% YoY in Q3 2026 due to increased capex, higher tax payments, lower working capital inflows, higher operating costs and lower gold sold
  • · Sukari gold production fell 21% YoY, driven by Stage 5 ore mined in Q3 2025 and lower-grade material in Q3 2026
  • · TRIFR at managed operations rose to 1.09 from 0.79 in Q2 2026
  • · Total cash costs at managed operations rose to $1,597/oz (from $1,244/oz), with AISC at managed operations at $2,273/oz (from $1,766/oz)
  • · Siguiri rose 49% YoY to 58,000oz after a TSF-related plant stoppage in Q3 2025; Sunrise Dam (+6%), Kibali (+6%), Cuiabá (+4%) and Cerro Vanguardia (+2%) also grew
  • · Total borrowings reduced to $1,804M from $2,301M a year earlier
  • · Average gold price received rose 21% YoY to $4,239/oz (Q3) and 40% YoY to $4,518/oz (9M)
LINCOLN NATIONAL CORP 8-K mixed materiality 8/10

05-11-2026

Lincoln Financial reported Q3 2026 net income available to common stockholders of $1.3 billion, or $6.77 per diluted share, including a $0.47 unfavorable impact from the annual assumption review; adjusted operating income available to common stockholders was $339 million, or $1.72 per diluted share, versus $397 million ($2.04) in Q3 2025. Results were mixed: Life Insurance (operating income up $76 million YoY) and Retirement Plan Services (up 20% YoY) improved, while Group Protection fell sharply (operating income down 69% YoY to $46 million, margin 3.3%) on unfavorable disability experience and Annuities operating income declined 5% YoY to $294 million. The company resumed $50 million of share repurchases, retired $437 million of preferred stock via tender offers, and holding company available liquidity net of prefunding rose to $1.0 billion.

  • · Group Protection disability loss ratio rose 6 percentage points YoY, driven by higher claim severity and moderating incidence from favorable levels
  • · Annuities net outflows of $2.7B were driven by traditional variable annuity and RILA outflows, versus $1.1B net outflows a year earlier
  • · Retirement Plan Services swung to $1.9B net outflows from $755M net inflows in the prior-year quarter, with deposits down 29% on lower mid-large market first-year sales
  • · Life Insurance Q3 2026 operating income benefited from higher alternative investment income ($53M above return target), improved mortality, and the Q4 2025 captive consolidation
  • · Annuities return on average account balances improved to 65 bps from 63 bps in Q1 2026 (second consecutive quarterly improvement), though below the 73 bps of Q3 2025
  • · Management described Group Protection results as falling short of expectations, with underlying fundamentals still considered solid
  • · Net income of $1.3B was inflated by non-economic market risk benefit changes and investment and product-feature adjustments, which are excluded from adjusted operating income
HF Sinclair Corp 8-K neutral materiality 6/10

05-11-2026

HF Sinclair entered into a Stock Purchase Agreement dated November 3, 2026 to repurchase 2,100,000 common shares from REH Advisors Inc. at $110.81 per share, for an aggregate purchase price of approximately $233 million, funded with cash on hand and expected to close on or around November 6, 2026. This is the twenty-fourth privately negotiated repurchase from REH under the $1.5 billion Share Repurchase Program authorized August 26, 2026; cumulative repurchases under the program total $1 billion, leaving approximately $493 million of authorization remaining.

  • · Shares will be held as treasury stock by the Company
  • · Repurchase price of $110.81 per share is a privately negotiated price
  • · REH Advisors Inc. is now the parent company of REH Company, LLC (formerly The Sinclair Companies)
  • · Repurchase program may be discontinued at any time by the Board; future repurchases from REH depend on market and corporate considerations
  • · Further background on REH's relationship with the Company is in the Definitive Proxy Statement filed March 31, 2026
  • · Exhibit 10.1 (Stock Purchase Agreement) filed herewith
GRAHAM CORP 8-K mixed materiality 7/10

05-11-2026

Graham Corporation (NYSE: GHM) reported Q2 fiscal 2027 net sales of $69.8 million, up 6% YoY, driven by the FlackTek acquisition ($9.5 million contribution) and Space growth, while Energy & Process sales fell 17% and Defense sales rose 12%. Gross margin expanded 650 bps to 28.2%, adjusted EBITDA rose 64% to $10.3 million, and record backlog reached $561.3 million, though orders declined 11% YoY to $73.7 million. The company reaffirmed net sales and adjusted EBITDA guidance and raised its gross margin and SG&A guidance ranges.

  • · Orders declined 11% YoY to $73.7M, and Energy & Process sales fell 17%, offsetting Defense and Space growth
  • · Net sales growth of 6% excluded roughly $10.0M of lower material receipts, which masked underlying Defense softness
  • · Year-to-date operating margin contracted 50 bps to 7.1% despite strong quarterly margin gains
  • · Space backlog up 108% YoY; approximately 83% of backlog is Defense
  • · Adjusted net income per diluted share up 68% to $0.52 versus $0.31 prior year
  • · FY27 gross margin guidance raised to 25.0%-26.0% and SG&A guidance raised to 17.5%-18.5% of sales, with capex guidance reduced to $15M-$20M
REGIS CORP 10-Q mixed materiality 6/10

05-11-2026

Regis Corp reported Q1 FY2027 (quarter ended September 30, 2026) total revenue of $54.3 million, down 7.8% from $59.0 million a year earlier, with operating income falling 10.4% to $5.3 million. Net income declined 61.4% to $0.5 million ($0.21 basic EPS vs. $0.56), though diluted EPS and comprehensive income also fell, and total debt was reduced by roughly $8.5 million in the quarter. Performance was mixed: franchise rental income, royalties, and company-owned salon revenue all declined, while the balance sheet showed modest cash decline and a shrinking lease and debt base.

  • · Long-term debt was reduced by $7.9M via repayments, plus $0.6M of revolving credit facility repayments, during the quarter.
  • · Franchise rent expense and franchise rental income both declined 13.5%, indicating pass-through economics that offset each other.
  • · Gain on deferred compensation adjustment of $2.1M supported operating cash flow despite weaker earnings.
  • · Right-of-use assets fell from $175.7M to $168.7M and lease liabilities declined, reflecting a shrinking lease footprint.
  • · Broker fee asset decreased 9% to $3.7M, and total deferred revenue declined to $9.7M from $10.5M.
  • · Diluted EPS fell to $0.18 from $0.49, and diluted share count rose to 2.9M from 2.8M.
TAPESTRY, INC. 10-Q mixed materiality 8/10

05-11-2026

Tapestry, Inc. reported Q1 FY2027 (quarter ended September 26, 2026) net sales of $1,894M, up 11.1% from $1,705M a year earlier, with net income of $360M versus $275M (+30.9%) and diluted EPS of $1.76 versus $1.28 (+37.5%). Results were mixed on the balance sheet: total assets were roughly flat at $6,615M versus $6,692M, cash fell to $599M from $975M, inventories rose 27.7% to $1,055M, and stockholders' equity dropped to $344M from $692M as large share repurchases ($603M) and debt rebalancing weighed on capital.

  • · Net cash from operating activities more than doubled? No: rose 74.3% to $197M from $113M, though working capital absorbed cash via inventory (+$222M) and receivables (+$106M) build
  • · Gross margin expanded to about 78.6% from 76.3% prior year, while SG&A grew 9.4%, outpacing the 11.1% sales growth only modestly; operating margin improved to about 22.4% from 19.2%
  • · Total debt was about $2,557M, with $597M reclassified to current debt from zero at June 27, 2026, and long-term debt declining to $1,960M from $2,379M
  • · Accumulated deficit widened to $(3,545)M from $(3,210)M, reflecting repurchases recorded against retained earnings
  • · Share repurchases of $603M were 13.6% lower than the $698M in the prior-year quarter, and cash returns (buybacks plus dividends) totaled $695M
  • · Effective tax expense was $51M on $411M pre-tax income (about 12.4%), versus $44M on $319M (about 13.8%) prior year
  • · Accumulated other comprehensive loss widened to $(231)M from $(218)M, driven by foreign currency translation losses and cash flow hedge losses
Vontier Corp 8-K mixed materiality 7/10

05-11-2026

Vontier reported Q3 2026 sales of $736.9 million, down 2.1% year-over-year reflecting the Teletrac Navman divestiture, though core sales rose 5.7%. GAAP diluted EPS was $0.73 and adjusted diluted EPS was $0.92, while the company raised full-year 2026 adjusted diluted EPS guidance to $3.60–$3.64 and initiated Q4 adjusted EPS guidance of $0.99–$1.03. Performance was mixed: Mobility Technologies sales fell 13.7% and Repair Solutions sales slipped 0.9% with segment margin down 180 bps, offsetting strength in Environmental & Fueling Solutions (sales up 8.7%, core up 13.1%).

  • · Mobility Technologies segment margin rose 740 bps to 25.9% despite a 13.7% sales decline
  • · Repair Solutions segment operating profit fell 9.5% with margin down 180 bps on unfavorable mix and lower interest income
  • · Net earnings declined 3.7% YoY to $99.0M despite higher operating profit, due to a higher tax provision ($44.1M vs $33.2M)
  • · Year-to-date gain/loss on sale of business shows an $86.1M loss versus a $3.4M gain in the prior year period
  • · Cash and equivalents fell to $258.4M from $492.2M at year-end 2025; long-term debt essentially flat at $1,595.5M
Shutterstock, Inc. 10-Q negative materiality 9/10

05-11-2026

Shutterstock reported Q3 2026 revenue of $173.9 million, down 33.1% from $260.1 million in Q3 2025, and a net loss of $197.8 million (EPS of -$5.35) driven primarily by a $203.3 million goodwill impairment. For the nine months, revenue fell 22.7% to $594.9 million and the net loss widened to $401.3 million, including $377.1 million in goodwill impairment charges. Operating cash flow declined 72.2% to $36.2 million for the nine months, and cash fell to $110.5 million from $178.2 million at year-end 2025.

  • · Q3 2026 goodwill impairment of $203.3M and nine-month impairment of $377.1M drove the operating loss; goodwill fell from $574.6M to $196.9M
  • · Q3 2026 gross margin contracted to roughly 51.9% from roughly 60.6% a year earlier, as cost of revenue fell more slowly than revenue
  • · Operating expenses excluding goodwill impairment decreased, with sales and marketing down 23.9%, product development down 36.4%, and G&A down 36.0% in Q3
  • · Other expense, net swung to a $14.4M expense for nine months 2026 versus $30.3M income in nine months 2025, largely due to unrealized losses on investments ($17.9M) versus gains in the prior year
  • · Deferred tax assets rose to $79.4M from $61.3M, while Q3 2026 recorded a $2.8M tax benefit versus an $18.0M provision in Q3 2025
  • · Accumulated other comprehensive loss widened to $10.1M from $4.8M, reflecting foreign currency translation losses
  • · Cash dividends paid totaled $26.0M for nine months 2026 versus $34.8M in 2025, while the company repaid $31.6M on its credit facility
  • · Total debt (current plus long-term) declined to $242.5M from $274.7M at year-end 2025
  • · Working capital turned lower: current assets fell to $256.8M from $338.6M while current liabilities fell only to $543.2M from $628.4M
  • · Accounts receivable decreased to $100.5M from $112.6M, and deferred revenue declined to $189.7M from $213.0M, signaling softer forward billings
Avalo Therapeutics, Inc. 10-Q mixed materiality 8/10

05-11-2026

Avalo Therapeutics reported a Q3 2026 net loss of $18.9M ($0.34 per share) versus a $30.6M loss in Q3 2025, an improvement driven by a $4.2M quarter interest income and a $0.2M derivative fair value gain versus a $12.5M derivative loss a year earlier. Operating expenses rose 21.9% YoY to $23.4M as R&D grew 10.5% and G&A grew 49.8%, while nine-month net loss widened 16.1% to $74.9M. Cash, cash equivalents and investments rose sharply to roughly $463M after a $431.3M gross public offering, though operating cash burn for the nine months was $49.2M.

  • · G&A expense rose 49.8% YoY in Q3 2026 to $8.4M, outpacing R&D growth of 10.5%
  • · Nine-month operating cash burn increased 32.2% YoY to $49.2M
  • · Net loss per share improved to $(0.34) in Q3 2026 from $(2.19), but the share count increased roughly 3.9x (weighted average 55.1M vs. 14.0M), diluting per-share comparisons
  • · Change in fair value of contingent consideration of $6.6M (9M 2026) reflects AlmataBio-related liability revaluation; $4.8M of contingent consideration was paid in the period
  • · Other comprehensive loss on investments of $(1.5M) for 9M 2026 reversed prior-year gains, and accumulated OCI turned negative
Amylyx Pharmaceuticals, Inc. 10-Q mixed materiality 7/10

05-11-2026

Amylyx Pharmaceuticals reported a Q3 2026 net loss of $45.5M ($0.38 per share), versus a $34.4M loss in Q3 2025, as operating expenses rose 38% to $49.7M on higher R&D ($28.4M vs. $19.9M) and SG&A ($21.3M vs. $16.2M). Nine-month net loss widened to $130.2M from $111.7M, though cash, cash equivalents and marketable securities increased sharply to $768.1M at September 30, 2026, following a $544.6M financing in Q3. Net loss per share improved to $(1.15) from $(1.25) year-to-date, reflecting the much larger weighted-average share count.

  • · Q3 2026 IPR&D milestone charge of $4.0M, with matching milestone payment in investing activities
  • · Available-for-sale securities posted a $386K net unrealized loss for the nine months ended September 30, 2026
  • · Nine-month net cash used in operating activities widened to $102.0M from $95.4M
  • · Nine-month proceeds from option exercises and RSU vesting rose to $20.8M from $3.7M
  • · Stock-based compensation expense for the nine months was $24.8M versus $21.3M a year earlier
  • · Q3 2026 interest income rose to $4.2M from $1.8M, offsetting part of the larger operating loss
  • · Total stockholders' equity increased to $753.7M from $305.3M at year-end 2025
  • · Shares outstanding grew about 17% to 128.5M since December 31, 2025
BENTLEY SYSTEMS INC 8-K mixed materiality 7/10

05-11-2026

Bentley Systems reported Q3 2026 total revenues of $421.5M, up 12.2% YoY (12.7% constant currency), with ARR of $1,582.8M, up from $1,405.2M, and constant currency ARR growth of 13%. Operating income margin expanded to 29.1% from 22.5%, but operating cash flow declined to $109.4M from $116.4M and free cash flow fell to $101.4M from $110.7M, so quarterly cash generation was mixed despite strong growth. The company also divested Cohesive to Naviam and completed the acquisition of Eliis for seismic interpretation.

  • · Q3 2026 operating income rose to $122.6M from $84.5M YoY
  • · Net debt leverage of 1.7 times with an undrawn revolving credit facility
  • · Constant currency ARR growth range raised to 12.5-13.5% (excluding Cohesive divestiture)
  • · Cohesive divestiture completed October 13, 2026 in exchange for equity interest and warrants in Naviam
  • · Eliis acquisition completed October 29, 2026 to complement Seequent
  • · Interest expense rose to $9.9M in Q3 from $2.7M YoY
  • · Nearly 70% of Year in Infrastructure Awards finalists used AI in their projects
  • · 2027 convertible notes to be repaid at maturity
FATE THERAPEUTICS INC 8-K mixed materiality 6/10

05-11-2026

Fate Therapeutics reported Q3 2026 results with a net loss of $30.7 million ($(0.25) per share), down from a $32.3 million loss ($(0.27) per share) a year earlier, and total operating expenses of $32.2 million. Cash, equivalents and investments were $139.1 million, a quarterly decrease of $14.7 million; with a $15.0 million CIRM CLIN2 grant, runway extends to mid-2028. Clinical progress on FT819 in lupus nephritis (RECLAIM-LN Phase 2 enrolling across 17 sites) and the newly cleared FT839 Phase 1/2 COMPLETE trial was reported, though the update is mixed: cash declined quarter-over-quarter and early data rests on very small patient numbers.

  • · Cash runway was extended to mid-2028 only when the $15.0M CIRM grant is combined with the $139.1M cash balance
  • · FT819 bendamustine-regimen lupus nephritis data rests on only two patients with Month 6 follow-up, and one patient at Month 24
  • · Q3 2026 operating expenses of $32.2M were roughly 1 to 1.5 times the quarterly net loss, showing limited top-line offset
  • · FT836 solid tumor study update was qualitative only, with no quantitative response data disclosed
Cartesian Therapeutics, Inc. 10-Q mixed materiality 7/10

05-11-2026

Cartesian Therapeutics reported a Q3 2026 net loss of $11.5M, narrowing sharply from a $35.9M loss in Q3 2025, driven primarily by a $10.7M gain on the change in fair value of its contingent value rights (CVR) liability, which offset $15.6M of R&D expense. However, the company generated no revenue in the quarter versus $0.5M a year earlier, cash and equivalents declined to $123.0M from $125.1M at year-end 2025, and stockholders' deficit widened to $(130.5)M from $(126.2)M, with the company newly carrying $50.2M of long-term debt.

  • · Net cash used in operating activities widened to $70.9M for nine months 2026 from $56.2M in the prior-year period
  • · Purchases of property and equipment fell to $0.7M from $5.0M year over year
  • · Accounts receivable fell to $0.05M from $1.1M at year-end 2025
  • · Q3 2026 net loss per share of $(0.38) compares with $(1.38) in Q3 2025, reflecting both lower loss and a 16.5% increase in weighted-average shares
  • · Q3 2026 interest expense of $2.0M reflects the new long-term debt
  • · Derivative liability embedded in long-term debt was $8.6M at September 30, 2026, classified as Level 3
  • · Series A Preferred shares outstanding declined from 120,790 to 98,050 following conversions into common stock
  • · Nine-month 2026 operating loss of $80.7M compares with $64.8M, driven by higher R&D spending
Monte Rosa Therapeutics, Inc. 8-K mixed materiality 7/10

05-11-2026

Monte Rosa Therapeutics reported Q3 2026 results with collaboration revenue of $54.4M, up from $12.8M a year earlier, driven by a $50.0M Novartis milestone, and net income of $3.1M versus a $27.1M net loss in Q3 2025. However, R&D expenses rose 24% YoY to $45.4M and G&A rose 20% YoY to $10.9M, and cash, cash equivalents, restricted cash, and marketable securities declined $43.4M sequentially to $582.6M as of September 30, 2026. The company also reported positive Phase 1 GFORCE-1 data for MRT-8102 and advanced several Phase 2 programs, with the cash balance expected to fund operations into 2029.

  • · Net income of $3.1M in Q3 2026 was driven by one-time milestone revenue; the company had a $27.1M net loss in Q3 2025
  • · Cash position declined $43.4M sequentially, primarily from operational cash use, despite the $50.0M Sjögren's milestone
  • · Cash receipts from the $50.0M and $37.5M milestones are not reflected in the September 30 cash balance
  • · CDK2 and CCNE1 IND submissions have slipped to 2027, and the next-generation NEK7 IND is now expected in 2027 due to Phase 2 prioritization
  • · GFORCE-1 showed no serious adverse events and placebo-like adverse event rates for MRT-8102, with median NEK7 degradation of roughly 80% to 90%
  • · The MODeFIRe-1 and enzalutamide combination updates are expected in 2027 and by year-end 2026, respectively
KIMBERLY CLARK CORP 4 neutral materiality 3/10

04-11-2026

Director Perry Kirk was awarded 300 Restricted Share Units.

  • · Director Perry Kirk was awarded 300 Restricted Share Units
PAPA JOHNS INTERNATIONAL INC 10-Q negative materiality 7/10

05-11-2026

Papa John's reported Q3 2026 total revenues of $454.8M, down 10.5% YoY from $508.2M, with operating income falling 12.0% to $14.2M from $16.2M. Net income attributable to the Company declined 33.4% to $3.1M, and diluted EPS fell to $0.09 from $0.13. Nine-month revenues declined 9.0% to $1,415.8M, while nine-month net income attributable to the Company fell 19.3% to $18.9M, and cash from operations dropped 44.9% to $58.5M.

  • · Company-owned restaurant sales fell 22.1% YoY in Q3 to $131.3M, the steepest decline among revenue lines, reflecting refranchising activity
  • · Total stockholders' deficit widened to $(438.5)M from $(433.7)M at fiscal year-end, with $1.21B in total liabilities against $772.8M in assets
  • · Cash balance declined to $26.8M from $36.95M at December 28, 2025, and nine-month net cash used in investing and financing activities totaled $18.8M and $49.7M respectively
  • · Accrued expenses and other current liabilities decreased $28.8M in the nine months, a major drag on operating cash flow
  • · Dividends were $0.92 per share for nine months, but declared Q3 dividend was $0.00 per share in the quarter
  • · Gain on dispositions and refranchising of $16.0M in proceeds supported investing cash flow during the nine months
Genprex, Inc. 8-K mixed materiality 3/10

05-11-2026

Genprex, Inc. (Nasdaq: GNPX) announced translational analysis results from whole-blood transcriptomes of 11 lung cancer patients treated with its lead candidate REQORSA (quaratusugene ozeplasmid), presented as a poster at the Gerontological Society of America 2026 Annual Scientific Meeting (November 4-7, 2026). The company characterizes the findings as a shift toward cellular repair and maintenance pathways, and as suggesting TUSC2 is involved in aspects of human aging. The analysis is exploratory, preclinical-adjacent in framing, and carries no reported financial figures; the filing also flags ongoing going-concern and Nasdaq continued-listing risks.

  • · At 5 hours post-dosing, the blood transcriptional response was dominated by innate immune, interferon, nucleic-acid-sensing, and chemokine pathways, which the company says is most consistent with a nonspecific host reaction to the lipid nanoparticle delivery system.
  • · At 24 hours, oxidative phosphorylation genes had recovered from a transient suppression seen at 5 hours, while ribosomal, translational, and IGF/mTOR-associated growth pathways were suppressed over the same period.
  • · Preclinical data from the Meharry collaboration indicate TUSC2 modulates cancer immune responses by boosting Natural Killer (NK) cell antitumor activity, and separately published peer-reviewed data link TUSC2 to maintaining cellular function during brain aging.
  • · The filing is a forward-looking, exploratory update: the company itself notes the findings are not a guarantee of any clinical, regulatory, or aging-related outcome, and the analysis is based on a small sample of 11 patients.
  • · Forward-looking risk factors explicitly reference the company's ability to maintain Nasdaq Capital Market continued listing compliance and to continue as a going concern, which are not quantified in this filing.
Charming Medical Ltd 6-K negative materiality 8/10

05-11-2026

Charming Medical Limited (Nasdaq: MCTA) disclosed in a 6-K filed November 5, 2026 that it received a Nasdaq delisting determination letter dated October 29, 2026, following an SEC trading suspension issued November 11, 2025 over alleged social-media-driven price manipulation. Unless the Company requests an appeal by November 5, 2026, trading will be suspended at the open on November 9, 2026, with the securities subsequently removed from Nasdaq listing and registration. The company states that Nasdaq has not found any wrongdoing by the company and that the delisting does not affect ongoing business operations, though OTC trading may be possible with no assurance of an active market.

  • · SEC order suspending trading was issued November 11, 2025, citing potential manipulation via unknown persons on social media urging screenshot-documented buying, holding, or selling
  • · Nasdaq cited Listing Rule IM-5101-4 as the basis for delisting, which permits delisting based on potential third-party misconduct where the SEC has imposed a temporary trading suspension
  • · Company will consult legal counsel and advisors on next steps and will make further announcements as appropriate
  • · Nasdaq has not communicated any finding that the Company engaged in wrongdoing
WW INTERNATIONAL, INC. 8-K mixed materiality 7/10

05-11-2026

WW International reported Q3 2026 revenue of $152.9 million, down 11% year-over-year, while Clinical Subscription Revenue grew 48% to $38.0 million and reached 25% of total revenue (up from 15%). Net income was $15.1 million (9.9% margin) versus a $57.5 million net loss in Q3 2025, and Adjusted EBITDA rose 21% to $51.7 million (33.8% margin). The company narrowed full-year 2026 revenue guidance to $625–$630 million, which is below the prior midpoint range, and raised the low end of Adjusted EBITDA guidance to $110–$115 million.

  • · Adjusted gross margin and GAAP gross margin both declined year-over-year, despite a year-over-year increase in Clinical revenue mix
  • · Adjusted EBITDA improvement was attributed partly to lower marketing spend versus Q3 2025, which included product launch investment
  • · Revenue guidance was narrowed with a lower high end ($630M vs $635M) while the low end was raised ($625M vs $620M)
  • · Stephen Bye became CEO on October 1, 2026, following the period end
  • · Company emerged from Chapter 11 on June 24, 2025; post-emergence results use Successor presentation and are not directly comparable to pre-emergence periods
Critical Metals Corp. 4 negative materiality 5/10

04-11-2026

Chief Financial Officer Savchenko Sergey sold 66,667 Ordinary Shares par value $0.001 at $6.81 (~$454K). Savchenko Sergey holds 93,333 shares after the transaction.

  • · Chief Financial Officer Savchenko Sergey sold 66,667 Ordinary Shares par value $0.001 at $6.81 (~$454K)
Palantir Technologies Inc. 4 negative materiality 3/10

04-11-2026

Director Stat Lauren Elaina Friedman sold 1,358 Class A Common Stock at $186.29 (~$253K). Stat Lauren Elaina Friedman holds 45,044 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · Director Stat Lauren Elaina Friedman sold 1,358 Class A Common Stock at $186.29 (~$253K)
Janus Living, Inc. S-11MEF neutral materiality 3/10

04-11-2026

Janus Living, Inc. filed an S-11MEF registration statement with the SEC on November 4, 2026, to register an additional $12,362,500 of Class A-1 common stock under Rule 462(b), related to its prior S-11 registration (File No. 333-299816) declared effective the same day. The filing is a procedural step to increase the offering size, with no new financial data or operational changes disclosed.

  • · The filing is made under Rule 462(b) and incorporates by reference the prior S-11 registration statement (File No. 333-299816).
  • · The prior registration statement was declared effective on November 4, 2026.
  • · The company is a non-accelerated filer and an emerging growth company.
  • · The company has not elected to use the extended transition period for complying with new or revised financial accounting standards.
  • · The additional securities are of the same class as those covered by the prior registration statement.
Churchill Capital Corp XI SC 13D/A neutral materiality 5/10

04-11-2026

Churchill Sponsor XI LLC, M. Klein Associates, Inc., and Michael Klein filed Amendment No. 2 to their Schedule 13D, reporting beneficial ownership of 14,597,500 shares (6.02%) of Churchill Capital Corp XI common stock following the completion of the Domestication and Merger on November 2 and November 4, 2026, respectively. The ownership includes 14,525,000 shares of common stock and 72,500 shares underlying private placement warrants. Michael Klein, the former CEO and Chairman, disclaims beneficial ownership except to the extent of his pecuniary interest.

  • · The Domestication and Merger were completed on November 2, 2026, and November 4, 2026, respectively.
  • · Each of the 13,800,000 Class B ordinary shares held by the Sponsor converted into Class A ordinary shares on a one-for-one basis, and then into common stock upon Domestication.
  • · The 725,000 private placement units (including 225,000 units issued upon settlement of working capital loans) separated into one share and one-tenth of a warrant per unit; warrants become exercisable 30 days after the Merger.
  • · The A&R Registration Rights Agreement and Advisory Agreement became effective upon completion of the Merger.
  • · No transactions in ordinary shares or common stock were effected by the Reporting Persons during the 60 days preceding the report date.
PROCORE TECHNOLOGIES, INC. 4 negative materiality 3/10

04-11-2026

Director O CONNOR KEVIN J sold 7,582 Common Stock at $60.52 (~$459K). 4 transactions reported in total. O CONNOR KEVIN J holds 892,902 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · Director O CONNOR KEVIN J sold 5,769 Common Stock at $54.36 (~$314K)
  • · Director O CONNOR KEVIN J sold 1,923 Common Stock at $55.02 (~$106K)
  • · Director O CONNOR KEVIN J sold 7,582 Common Stock at $60.52 (~$459K)
  • · Director O CONNOR KEVIN J sold 110 Common Stock at $61.03 (~$6.71K)
Warburg Pincus Access Fund, L.P. 4 neutral materiality 3/10

04-11-2026

Director Fuchs Christine was awarded 750.59 Class E Limited Partnership Units at $33.30 (~$25K). Fuchs Christine holds 30,062.63 shares after the transaction.

  • · Director Fuchs Christine was awarded 750.59 Class E Limited Partnership Units at $33.30 (~$25K)
Natera, Inc. 4 negative materiality 3/10

04-11-2026

PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 760 Common Stock at $415.52 (~$316K). 12 transactions reported in total. Moshkevich Solomon holds 101,323 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 9 Common Stock at $388.20 (~$3.49K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 410 Common Stock at $400.29 (~$164K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 200 Common Stock at $405.26 (~$81.1K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 432 Common Stock at $406.94 (~$176K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 408 Common Stock at $408.08 (~$166K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 520 Common Stock at $409.46 (~$213K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 120 Common Stock at $410.72 (~$49.3K)
  • · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 120 Common Stock at $411.73 (~$49.4K)
Churchill Capital Corp XI 4 neutral materiality 6/10

04-11-2026

See Remarks Klein Michael Stuart exercised/converted 14,525,000 Common Stock. Klein Michael Stuart holds 14,525,000 shares after the transaction.

  • · See Remarks Klein Michael Stuart exercised/converted 14,525,000 Common Stock
  • · See Remarks Klein Michael Stuart exercised/converted 13,800,000 Class B ordinary shares
  • · See Remarks Klein Michael Stuart acquired 72,500 Warrant (Right to Buy)
Natera, Inc. 4 negative materiality 3/10

04-11-2026

Director Sheena Jonathan sold 109 Common Stock at $400.29 (~$43.6K). Sheena Jonathan holds 217,574 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · Director Sheena Jonathan sold 3 Common Stock at $388.20 (~$1.16K)
  • · Director Sheena Jonathan sold 109 Common Stock at $400.29 (~$43.6K)
Natera, Inc. 4 negative materiality 3/10

04-11-2026

SEC. AND CHIEF LEGAL OFFICER RABINOWITZ DANIEL sold 334 Common Stock at $400.29 (~$134K). RABINOWITZ DANIEL holds 167,880 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · SEC. AND CHIEF LEGAL OFFICER RABINOWITZ DANIEL sold 7 Common Stock at $388.20 (~$2.72K)
  • · SEC. AND CHIEF LEGAL OFFICER RABINOWITZ DANIEL sold 334 Common Stock at $400.29 (~$134K)
Warburg Pincus Access Fund, L.P. 4 neutral materiality 3/10

04-11-2026

Director Herbert Cecilia Healy was awarded 750.59 Class E Limited Partnership Units at $33.30 (~$25K). Herbert Cecilia Healy holds 10,974.85 shares after the transaction.

  • · Director Herbert Cecilia Healy was awarded 750.59 Class E Limited Partnership Units at $33.30 (~$25K)
Natera, Inc. 4 negative materiality 3/10

04-11-2026

EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 731 Common Stock at $400.29 (~$293K). Rabinowitz Matthew holds 2,116,928 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 17 Common Stock at $388.20 (~$6.6K)
  • · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 731 Common Stock at $400.29 (~$293K)
Natera, Inc. 4 negative materiality 4/10

04-11-2026

PRESIDENT, CHIEF BUS. OFFICER Fesko John sold 295 Common Stock at $400.29 (~$118K). Fesko John holds 195,276 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · PRESIDENT, CHIEF BUS. OFFICER Fesko John sold 7 Common Stock at $388.20 (~$2.72K)
  • · PRESIDENT, CHIEF BUS. OFFICER Fesko John sold 295 Common Stock at $400.29 (~$118K)
Natera, Inc. 4 negative materiality 5/10

04-11-2026

CEO AND PRESIDENT Chapman Steven Leonard sold 2,866 Common Stock at $415.64 (~$1.19M). Chapman Steven Leonard holds 87,431 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · CEO AND PRESIDENT Chapman Steven Leonard sold 21 Common Stock at $387.90 (~$8.15K)
  • · CEO AND PRESIDENT Chapman Steven Leonard sold 914 Common Stock at $400.29 (~$366K)
  • · CEO AND PRESIDENT Chapman Steven Leonard sold 2,866 Common Stock at $415.64 (~$1.19M)
Natera, Inc. 4 negative materiality 4/10

04-11-2026

CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 470 Common Stock at $391.49 (~$184K). Brophy Michael Burkes holds 45,779 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 8 Common Stock at $388.03 (~$3.1K)
  • · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 317 Common Stock at $400.29 (~$127K)
  • · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 470 Common Stock at $391.49 (~$184K)
Warburg Pincus Access Fund, L.P. 4 neutral materiality 3/10

04-11-2026

Director Fichera Alfred was awarded 375.29 Class E Limited Partnership Units at $33.30 (~$12.5K). Fichera Alfred holds 7,487.42 shares after the transaction.

  • · Director Fichera Alfred was awarded 375.29 Class E Limited Partnership Units at $33.30 (~$12.5K)
Core Natural Resources, Inc. 8-K mixed materiality 7/10

05-11-2026

Core Natural Resources (NYSE: CNR) reported Q3 2026 net income of $9.0 million ($0.18 per diluted share), adjusted EBITDA of $165.2 million (including $17.2 million of nine-month discretionary incentive compensation), and revenues of $1.1 billion. The company repurchased 930,611 shares for $84.7 million and declared a $0.10 quarterly dividend, while volumes were mixed: High CV Thermal sales fell 2% QoQ and per-ton cash costs rose across thermal and metallurgical segments, though Powder River Basin volumes rose 32% QoQ and realized pricing improved in metallurgical coal.

  • · Powder River Basin realized price was roughly flat QoQ at $14.29 per ton while cash cost fell 9% to $13.49, flipping cash margin positive at $0.80 per ton from -$0.57 in Q2
  • · High CV Thermal cash margin per ton fell about 21% year over year, from $19.25 to $15.14
  • · Metallurgical sales were hurt by late-quarter storms that pushed two high-value vessel loadings into early October
  • · Core has returned about 85% of cumulative free cash flow since February 2025, against a 75% target
  • · 2026 guidance: 88.0-91.5 million total tons; High CV Thermal cash cost $40.00-41.00/ton; Metallurgical cash cost $88.00-90.00/ton; capex $325-375 million; D&A $600-650 million; cash tax rate 0-5%
  • · Q3 cash flow included $174.6M operating cash flow, $94.4M capex, and $84.7M buybacks; cash and restricted cash fell $43.5M in the quarter
HONDA MOTOR CO LTD 4 neutral materiality 4/10

05-11-2026

Director Higashi Kazuhiro was awarded 66 Common Stock at $11.46 (~$756). Higashi Kazuhiro holds 190 shares after the transaction.

  • · Director Higashi Kazuhiro was awarded 66 Common Stock at $11.46 (~$756)
Cigna Group 8-K mixed materiality 8/10

05-11-2026

The Cigna Group reported third quarter 2026 total revenues of $73.7 billion, up 6% from third quarter 2025, while shareholders' net income fell to $1.4 billion ($5.47 per share) from $1.9 billion ($6.98 per share), mainly due to the absence of a prior-year after-tax gain on sale. Adjusted income from operations was $2.1 billion ($7.98 per share), essentially flat versus $2.1 billion ($7.83 per share) a year earlier, as Pharmacy Benefit Services profit declined 22% while Cigna Healthcare and Specialty and Care Services grew. The company raised its full-year 2026 adjusted EPS outlook to at least $30.60 and announced long-term targets and a $3 billion 'Accelerate to One' modernization initiative at its 2026 Investor Day.

  • · Specialty and Care Services adjusted revenues rose only about 1% YoY as lower specialty pharmacy revenue from biosimilar and generic adoption offset strong specialty distribution growth.
  • · Cigna Healthcare MCR rose to 85.0% from 84.8% YoY, driven by U.S. Employer business mix, partially offset by lower MCR in Individual and Family Plans.
  • · The company plans to exit the Individual and Family Plans medical business effective January 1, 2027.
  • · Total behavioral customers fell 19% since year-end 2025 due to termination of a government contract, with minimal financial impact.
  • · The 2026 Cigna Healthcare MCR outlook was narrowed by 50 bps to 84.2% +/- 25 bps.
  • · Long-term targets include a 10%-14% adjusted EPS CAGR and roughly $50B in cumulative operating cash flow through 2030.
  • · SG&A expense ratio rose to 4.9% from 4.8% YoY, reflecting investments in long-term growth partially offset by efficiencies.
XCel Brands, Inc. DEFR14A neutral materiality 5/10

04-11-2026

Xcel Brands filed a definitive proxy statement for its 2026 Annual Meeting on December 18, 2026, asking stockholders to elect five directors, ratify Wolf & Company as auditor, expand the 2021 Equity Incentive Plan by 650,000 shares (from 1,150,000 to 1,800,000), and approve issuance of over 19.99% of outstanding common stock upon conversion of secured promissory notes in an event of default. The company had 6,908,839 shares outstanding as of the October 19, 2026 record date, with no preferred stock outstanding.

  • · Annual Meeting to be held Friday, December 18, 2026 at 12:00 PM local time at 550 Seventh Avenue, 11th Floor, New York, NY 10018
  • · Record date for voting: October 19, 2026
  • · 6,908,839 shares of common stock outstanding as of the record date; no preferred stock outstanding
  • · Proposal 3 seeks to increase shares reserved under the 2021 Plan by 650,000 shares, from 1,150,000 to 1,800,000
  • · Proposal 4 seeks approval to issue in excess of 19.99% of outstanding common stock upon conversion of certain secured promissory notes upon an event of default
  • · Five director nominees to be elected by majority of votes present in person or by proxy
  • · Wolf & Company, PC proposed for ratification as independent registered public accounting firm for fiscal year ending December 31, 2026
  • · Company is using the notice-only option for proxy materials, available at www.cstproxy.com/xcelbrands/2026
  • · Quorum requires a majority of shares entitled to vote present in person or by proxy
BRIGHTHOUSE LIFE INSURANCE Co OF NY S-3 neutral materiality 3/10

25-05-2022

Brighthouse Life Insurance Co of NY filed an S-3 shelf registration statement with the SEC on May 25, 2022, to register the Brighthouse Shield Level Select 6-Year Annuity. The filing incorporates by reference the company's future periodic reports (10-K, 10-Q, 8-K) and includes disclaimers from index publishers S&P Dow Jones Indices, Frank Russell Company, and MSCI Inc., stating they do not sponsor, endorse, or guarantee the annuity product. The registration statement contains placeholder sections for audited financial statements and other details to be updated by amendment.

  • · Filing type is S-3 under the Securities Act of 1933
  • · SEC file number: 333-265199
  • · Company formerly known as First MetLife Investors Insurance Co (name changed February 15, 2002)
  • · Company incorporated in New York, fiscal year ends December 31
  • · Business address: 285 Madison Avenue, 14th Floor, New York, NY 10017
  • · The prospectus incorporates by reference future filings under Exchange Act Sections 13(a), 13(c), 14, and 15(d), but not 8-Ks furnished under Items 2.02 or 7.01
  • · Index publishers explicitly disclaim any liability, warranty, or endorsement of the annuity product

Get daily alerts with 14 investment signals, 10 risk alerts, 9 opportunities and full AI analysis of all 50 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Pre-Market SEC Filings Roundup

🇺🇸 More from United States

View all →